Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics

By Lips E.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 827-836

Springer Publishing Company

Access to resources Recommend Favorite

TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy

By Wang Jiayu  

Breast Cancer Research and Treatment, Vol. 135, Iss. 2, 2012-09 ,pp. : 531-537

Springer Publishing Company

Access to resources Recommend Favorite

Spotlight on Trastuzumab in Metastatic Breast Cancer Overexpressing HER2

By McKeage K.   Perry C.M.  

American Journal of Cancer, Vol. 1, Iss. 3, 2002-03 ,pp. : 217-221

Adis International

Access to resources Recommend Favorite

HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer

By Tulbah Asma   Ibrahim Ezzeldin   Ezzat Adnan   Ajarim Dahish   Rahal Mohammed   Weshi Amr   Sorbris Ralph  

Medical Oncology, Vol. 19, Iss. 1, 2002-03 ,pp. : 15-23

Humana Press, Inc

Access to resources Recommend Favorite

Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer

By          

Experimental and Therapeutic Medicine, Vol. 3, Iss. 1, 2012-01 ,pp. : 66-71

Spandidos Publications

Access to resources Recommend Favorite